ClinicalTrials.gg
RecruitingNCT06622941Updated Aug 4, 2026

Study to ONO-4538 in Patients With Rhabdoid Tumor

A Phase 2 interventional study of ONO-4538 in Rhabdoid Tumor, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 14 sites in Japan. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Study summary

Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors

02

Conditions studied

  • Rhabdoid Tumor

Browse trials for

03

In context

Rhabdoid Tumor

115 studies on the registry are indexed under Rhabdoid Tumor; 23 are open to participants now.

This study's planned enrollment of 23 is below the median of 28 across 98 interventional studies indexed under Rhabdoid Tumor.

Browse Rhabdoid Tumor studies →

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender: Not specified
  2. Age (at the time of consent): 1 year or older
  3. Patients who are or intolerant to one or more regimens of chemotherapy for rhabdoid Tumors
  4. Patients with advanced or recurrent rhabdoid Tumors not eligible for curative resection

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of active concurrent or complications
  2. Patients with spinal lesions expected to require radiation therapy or surgical intervention during the trial period
  3. Patients with concomitant central nervous system disorders other than AT/RT that are inadequately controlled or may lead to discontinuation of the drug
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    ONO-4538

    Drug: ONO-4538

Interventions

  • every 2 weeks

    Also known as: Nivolumab

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Time frame: up to 4.5 years

Secondary outcomes

  1. Objective response rate (ORR) (site investigator assesment)

    Time frame: up to 4.5 years

  2. Overall survival (OS)

    Time frame: up to 4.5 years

  3. Progression free survival (PFS)

    Time frame: up to 4.5 years

  4. Disease control rate (DCR)

    Time frame: up to 4.5 years

  5. Time to response (TTR)

    Time frame: up to 4.5 years

  6. Best overall response (BOR)

    Time frame: up to 4.5 years

  7. Percent change from baseline in the sum of diameters of target lesions

    Time frame: up to 4.5 years

  8. Best reduction percent change from baseline in the sum of diameters of target lesions

    Time frame: up to 4.5 years

  9. Incidence of Adverse Events [Safety]

    Time frame: Up to 30 days after the last dose

07

Study locations

13 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jan 2029, 50 months after the start.

Of 23 phase 2 interventional studies under Rhabdoid Tumor, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 89. This study's planned 50 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 2, 2024
StartActual
Nov 25, 2024
Primary completionEst.
Jan 31, 2029
CompletionEst.
Mar 31, 2030
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06622941
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
Nov 25, 2024
Primary completion
Jan 31, 2029 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Aug 4, 2026

Study contacts

North America Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+18665877745(Toll-Free)
International Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+17162141777(Standard)
Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion